Compare Merck & Co., Inc. (MRK) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs BlackRock TCP Capital Corp — how do they compare? Merck & Co., Inc. trades at $133.35 (market cap $321.77B), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: Merck & Co., Inc. is far larger — about 982.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19.46%). Which is the better fit depends on your goals.
| MRK | TCPC | |
|---|---|---|
Market Cap | $321.77B | $327.64M |
Sector | Health | Financials |
52-Week High | $131.84 | $7.26 |
52-Week Low | $77.60 | $3.13 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.
The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
